Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration.

Several randomized clinical trials have demonstrated that IVA might potentially alleviate this burden by lengthening the injection interval without sacrificing visual or structural outcomes.[ 11 , 12 ] Although our study demonstrated real-world patterns align with the results observed in clinical trials,[ 25 ] such that almost half of patients in our study were able to extend their treatment intervals by 2 weeks or more compared to the period before switching, this finding did not reach statistical significance.

also in 111,027 other papers